Nemysis Limited – Fighting Deficiencies with Science

Nemysis Limited is a biotech company on a mission to tackle widespread nutritional disorders and deficiencies. Their focus? Bringing to market innovative solutions like IHAT – a next-generation oral iron supplement – and E40, a cutting-edge enzyme designed to protect people with Celiac Disease from accidental gluten exposure.

When Nemysis approached BEV Capital, their goal was clear: raise €5–7 million in equity to unlock a further €6.2 million in EU Horizon grant funding. This was a crucial step in scaling their impact and bringing their products to more patients worldwide.

BEV Capital supported Nemysis through every stage of the fundraising journey. From identifying the right investors and managing outreach, to gathering feedback and refining the approach, the collaboration was hands-on and adaptive. The process wasn’t just about introductions—it was about building a real strategy and momentum behind the raise.

The partnership gave Nemysis the visibility and traction they needed in a competitive space, helping position them as a compelling opportunity for biotech-focused investors.

And if Nemysis were a movie? It’d be Ironman. Their lead product is, after all, a powerful iron supplement. But the sequel’s already in the works—Justice League, where Ironman teams up with Glutensae40 to take down the global villain gluten, impacting over 8% of the population.